全文获取类型
收费全文 | 3040篇 |
免费 | 244篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 52篇 |
妇产科学 | 65篇 |
基础医学 | 456篇 |
口腔科学 | 27篇 |
临床医学 | 296篇 |
内科学 | 798篇 |
皮肤病学 | 107篇 |
神经病学 | 232篇 |
特种医学 | 107篇 |
外科学 | 485篇 |
综合类 | 39篇 |
一般理论 | 1篇 |
预防医学 | 132篇 |
眼科学 | 61篇 |
药学 | 174篇 |
中国医学 | 1篇 |
肿瘤学 | 234篇 |
出版年
2023年 | 10篇 |
2022年 | 25篇 |
2021年 | 61篇 |
2020年 | 42篇 |
2019年 | 75篇 |
2018年 | 75篇 |
2017年 | 37篇 |
2016年 | 70篇 |
2015年 | 86篇 |
2014年 | 129篇 |
2013年 | 165篇 |
2012年 | 240篇 |
2011年 | 257篇 |
2010年 | 125篇 |
2009年 | 120篇 |
2008年 | 210篇 |
2007年 | 212篇 |
2006年 | 171篇 |
2005年 | 179篇 |
2004年 | 187篇 |
2003年 | 160篇 |
2002年 | 121篇 |
2001年 | 17篇 |
2000年 | 16篇 |
1999年 | 20篇 |
1998年 | 36篇 |
1997年 | 19篇 |
1996年 | 23篇 |
1995年 | 20篇 |
1994年 | 20篇 |
1993年 | 22篇 |
1992年 | 14篇 |
1991年 | 13篇 |
1990年 | 12篇 |
1989年 | 23篇 |
1988年 | 24篇 |
1987年 | 23篇 |
1986年 | 8篇 |
1985年 | 17篇 |
1984年 | 9篇 |
1983年 | 13篇 |
1982年 | 12篇 |
1981年 | 14篇 |
1980年 | 11篇 |
1978年 | 9篇 |
1976年 | 10篇 |
1975年 | 11篇 |
1973年 | 7篇 |
1968年 | 9篇 |
1963年 | 8篇 |
排序方式: 共有3298条查询结果,搜索用时 31 毫秒
51.
52.
Tracey KAIN Jane ZOCHLING Andrew TAYLOR Nicholas MANOLIOS Malcolm D. SMITH Mark D. REED Matthew A. BROWN Lionel SCHACHNA 《International journal of rheumatic diseases》2008,11(1):45-49
Aim: To develop a set of Australian recommendations for the monitoring and treatment of ankylosing spondylitis (AS) through systematic literature review combined with the opinion of practicing rheumatologists. Methods: A set of eight questions, four in each domain of monitoring and treatment, were formulated by voting and the Delphi method. The results of a systematic literature review addressing each question were presented to the 23 participants of the Australian 3E meeting. All participants were clinical rheumatologists experienced in the daily management of AS. Results: After three rounds of breakout sessions to discuss the findings of the literature review, a set of recommendations was finalized after discussion and voting. The category of evidence and strength of recommendation were determined for each proposal. The level of agreement among participants was excellent (mean 84%, range 64–100%). Conclusions: The 12 recommendations developed from evidence and expert opinion provide guidance for the daily management of AS patients. For most recommendations, we found a paucity of supportive evidence in the literature highlighting the need for additional clinical studies. 相似文献
53.
54.
Nihar R. Desai Rolin L. Wade Pin Xiang Lionel Pinto Sasikiran Nunna Xin Wang Jason Exter Katherine E. Mues Mohdhar Habib ChiChang Chen 《Clinical cardiology》2021,44(5):715
BackgroundLow‐density lipoprotein cholesterol (LDL‐C) is a risk factor for atherosclerotic cardiovascular disease (ASCVD). There are limited real‐world data on LDL‐C lowering with evolocumab in United States clinical practice.HypothesisWe assessed LDL‐C lowering during 1 year of evolocumab therapy.MethodsThis retrospective cohort study used linked laboratory (Prognos) and medical claims (IQVIA Dx/LRx and PharMetrics Plus®) data. Patients with a first fill for evolocumab between 7/1/2015 and 10/31/2019 (index event) and LDL‐C ≥ 70 mg/dL were included (overall cohort; N = 5897). Additionally, a patient subgroup with a recent myocardial infarction (MI) within 12 months (median 130 days) before the first evolocumab fill was identified (N = 152). Reduction from baseline LDL‐C was calculated based on the lowest LDL‐C value recorded during a 12‐month follow‐up period.ResultsThe mean (SD) age was 65 (10) years; 61.9% of patients had ASCVD diagnoses and 70.7% of patients were in receipt of lipid‐lowering therapy. Following evolocumab treatment, changes in LDL‐C from baseline were −60% in the overall cohort (median [interquartile range (IQR)] 146 [115–180] mg/dL to 58 [36–84] mg/dL) and −65% in the recent MI subgroup (median [IQR] 137 [109–165] mg/dL to 48 [30–78] mg/dL). In the overall cohort and recent MI subgroup, 62.1% and 69.7% of patients achieved LDL‐C < 70 mg/dL, respectively.ConclusionsIn this real‐world analysis, evolocumab was associated with significant reductions in LDL‐C comparable to that seen in the FOURIER clinical trial, which were durable over 1 year of treatment. 相似文献
55.
Zervos M Mandell LA Vrooman PS Andrews CP McIvor A Abdulla RH de Caprariis PJ Knirsch CA Amsden GW Niederman MS Lode H 《Treatments in respiratory medicine》2004,3(5):329-336
Objective: To compare the efficacy and tolerability of ceftriaxone plus azithromycin with those of levofloxacin in the treatment of hospitalized patients with moderate to severe community-acquired pneumonia (CAP). Design: Randomized, open-label multicenter trial with 1 : 1 treatment allocation in an inpatient setting. Patients: 212 male or female inpatients with a clinical diagnosis of CAP were included in the study. In each treatment group >50% of patients had a pneumonia severity index of IV or V. Interventions: Open-label treatment with either intravenous (IV) ceftriaxone 1g and IV azithromycin 500mg daily or IV levofloxacin 500mg daily. Patients who improved clinically were switched to oral follow-on therapy with either azithromycin 500 mg/day or levofloxacin 500 mg/day. At the clinician’s discretion, oral cefuroxime axetil was added to the treatment regimen of patients who received oral azithromycin if a macrolide resistant pneumococcal isolate was documented. Results: Overall, both study treatments were well tolerated. Favorable clinical outcomes in clinically evaluable patients were demonstrated in 91.5% of patients treated with ceftriaxone plus azithromycin and 89.3% (95% CI ?7.1%, 11.4%) of patients treated with levofloxacin at the end of therapy visit and in 89.2% and 85.1% (95% CI ?6.7%, 14.8%) patients, respectively, at the end of study visit. Bacteriological eradication rates for both treatments were equivalent with the exception of Streptococcus pneumoniae; 44% of isolates were eradicated with levofloxacin compared with 100% of isolates with ceftriaxone plus azithromycin. Conclusions: As acknowledged by international CAP treatment guidelines, the combination of a third-generation cephalosporin and a macrolide is at least as efficacious as monotherapy with a fluoroquinolone with enhanced anti-pneumococcal activity, for hospitalized patients with moderate to severe CAP. Combined medication with a macrolide and third-generation cephalosporin may be preferred over fluoroquinolones as first-line therapy of hospitalized patients with CAP to minimize the development of multiresistant nosocomial Gram-negative bacilli. 相似文献
56.
Lionel H. Opie M. E. Speechly-Dick 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》1989,3(2):229-229
Page of the president of the International Society of Cardiovascular Pharmacology (ISCP) 相似文献
57.
Dr. Jean-Luc Faucheron M.D. Olivier Saint-Marc M.D. Lionel Guibert M.D. Rolland Parc M.D. 《Diseases of the colon and rectum》1996,39(2):208-211
METHODS: Forty-one consecutive patients with Crohn's disease who underwent long-term seton drainage for high transsphincteric, suprasphincteric, or extrasphincteric anal fistula from 1985 to 1993 were reviewed. The subsequent associated procedure was simple seton removal (18), secondary fistulotomy (7), rectal flap advancement (3), and proctectomy (2). Eleven patients still had the seton in place. RESULTS: Recurrence developed in seven patients (39 percent) undergoing simple seton removal and in one patient undergoing rectal flap advancement. None of the patients treated by secondary fistulotomy developed a recurrence. At the end of follow-up, five patients (12 percent) required proctectomy mainly for severe proctitis, and five patients (12 percent) developed anal incontinence, which was severe in two. CONCLUSION: Long-term seton drainage for high anal fistula in Crohn's disease is efficacious in both treating sepsis and preserving anal sphincter function. 相似文献
58.
Lionel Faivre Hélène Boucher Thomas Domet André Desproges Olivier Sibony Marina Bechard Valérie Vanneaux Jérôme Larghero Audrey Cras 《Transfusion》2018,58(2):520-531
After 30 years of hematopoietic stem cell use for various indications, umbilical cord blood is considered as an established source of cells with marrow and postmobilization peripheral blood. The limited number of cells still remains a problematic element restricting their use, especially in adults who require to be grafted with a higher cell number. Improving the quality of harvested cord blood, at least in terms of volume and amount of cells, is essential to decrease the number of discarded units. In this review, we examine several variables related to parturient, pregnancy, labor, delivery, collection, the newborn, umbilical cord, and placenta. We aim to understand the biologic mechanisms that can impact cord blood quality. This knowledge will ultimately allow targeting donors, which could provide a rich graft and improve the efficiency of the collection. 相似文献
59.
Lynne Moore Brahim Cisse Brice Lionel Batomen Kuimi Henry T. Stelfox Alexis F. Turgeon François Lauzier Julien Clément Gilles Bourgeois 《BMC health services research》2015,15(1):285
Background
Injury is second only to cardiovascular disease in terms of acute care costs in North America. One key to improving injury care efficiency is to generate knowledge on the determinants of resource use. Socio-economic status (SES) is a documented risk factor for injury severity and mortality but its impact on length of stay (LOS) for injury admissions is unknown. This study aimed to examine the relationship between SES and LOS following injury.This multicenter retrospective cohort study was based on adults discharged alive from any trauma center (2007–2012; 57 hospitals; 65,486 patients) in a Canadian integrated provincial trauma system. SES was determined using ecological indices of material and social deprivation. Mean differences in LOS adjusted for age, gender, comorbidities, and injury severity were generated using multivariate linear regression.Results
Mean LOS was 13.5 days. Patients in the highest quintile of material/social deprivation had a mean LOS 0.5 days (95 % CI 0.1-0.9)/1.4 days (1.1-1.8) longer than those in the lowest quintile. Patients in the highest quintiles of both social and material deprivation had a mean LOS 2.6 days (1.8-3.5) longer than those in the lowest quintiles.Conclusions
Results suggest that patients admitted for traumatic injury who suffer from high social and/or material deprivation have longer acute care LOS in a universal-access health care system. The reasons behind observed differences need to be further explored but may indicate that discharge planning should take patient SES into consideration.60.
Marc Bradette MD Dr. Michel Delvaux MD PhD Ghislain Staumont MD Jean Fioramonti DSc Lionel Bueno DSc Jacques Frexinos MD 《Digestive diseases and sciences》1994,39(6):1171-1178
Effects of octreotide (1.25 µg/kg subcutaneously) on colonic tone and visceral perception were evaluated in 10 IBS patients, using a barostat and compared to placebo in a double-blind crossover study. Colonic sensory thresholds were also studied in healthy controls for comparison with IBS patients. Colonic tone was reflected by variations in volume of the barostat balloon. Baseline volume was 117±38 ml and was not modified by placebo (122±40 ml) or octreotide (106±42 ml). After the meal, maximal decrease in balloon volume was 75±4% following placebo (P<0.001) beginning after 9±3 min and lasting 136±17 min. Following octreotide, the maximal decrease was 69±16% (NS vs placebo), after 10±3 min and lasting 140±22 min. In the second part, discomfort and pain thresholds were evaluated during isobaric distensions (4 mm Hg increments, 5-min duration, 5-min interval with return to pressure 0 between each). The pressure inducing discomfort was 21.2±5.9 mm Hg following placebo vs 29.6±6.6 mm Hg following octreotide (P<0.01). The pressure inducing pain was 24.8±7.3 mm Hg following placebo vs 33.2±7.3 mm Hg following octreotide (P<0.01). In healthy subjects, discomfort and pain were induced by colonic distensions at a mean intraballoon pressure of 32.7±5.8 mm Hg and 36.7±3.9 mm Hg, respectively. Compliance curves were not different following placebo and octreotide. Octreotide significantly increases thresholds for visceral perception in IBS patients without modifying compliance during distension nor colonic tone. 相似文献